New hope for hard-to-treat lung cancer? early trial launches
NCT ID NCT06931626
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 32 times
Summary
This early-stage study tests a new targeted drug (NMS-03305293) combined with chemotherapy (temozolomide) in people with small cell lung cancer that has returned after prior treatments. The main goals are to check safety and find the right dose. About 10 participants will be enrolled. This is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
Tennessee Oncology, PLLC
RECRUITINGNashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.